0R15 8780.0 -1.0593% 0R1E 8527.0 2.6237% 0M69 None None% 0R2V 234.75 9868.1529% 0QYR 1479.0 -3.7109% 0QYP 426.4 -0.6061% 0RUK None None% 0RYA 1496.0 -2.4772% 0RIH 168.8 0.0% 0RIH 169.0 0.1185% 0R1O 208.12 10254.2289% 0R1O None None% 0QFP None None% 0M2Z 267.9939 0.2127% 0VSO 31.38 -11.8663% 0R1I None None% 0QZI 574.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 164.74 0.3166%
Afya Ltd
Company Overview: Afya Ltd (NASDAQ: AFYA) is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy.
As per our previous US Diversified Opportunities report published on ‘AFYA’ on 09th November 2023, Kalkine provided a ‘Buy’ stance on the stock at USD 17.31 based on “decent fundamentals, healthy topline financial, dividend distribution & yield, associated risks, other key financial highlights” and the stock price has now moved by ~17.45% since then and the price has crossed resistance 1 and resistance 2.
Noted below are the details of support and resistance levels provided in our previous report:
AFYA’s Daily Chart
Considering the resistance around the range of USD 20.00 – USD 21.00, attainment of resistance 1 and resistance 2 levels, current trading levels, risks associated, and volatile market conditions on the back of rising interest rates, a ‘Sell’ rating is assigned to the “AFYA” at the current market price of USD20.33 (as of 24 November 2023, at 07:20 am PST).
Note: This report may be updated with details around fundamental and technical analysis, price/ chart in due course, as appropriate
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is November 24, 2023. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.
Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.
Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’
References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.
This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.
The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.
Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.
Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.